Benzinga | Nov 3, 2020 07:18AM EST

Baird Initiates Coverage On Editas Medicine with Underperform Rating, Announces Price Target of $14

Baird analyst Madhu Kumar initiates coverage on Editas Medicine (NASDAQ:EDIT) with a Underperform rating and announces Price Target of $14.